Lundbeck Q3 2019 Financial Results
Expand and Invest to Grow has significantly strengthened the pipeline
Project
Indication/label expansion
Phase I
Phase II (POC)
Phase III
Eptinezumab (anti-CGRP mAb)
Eptinezumab (anti-CGRP mAb)
Migraine prevention
Brexpiprazole
Filing
*
-2021
***
КККК
ККККК
Brexpiprazole
Brexpiprazole
Foliglurax (mGluR4 PAM)
Lu AF11167 (PDE 10 inhibitor)
Lu AG06466 (MGLLI)
Abilify Maintena 2-mth
Lu AF82422 (alpha-synuclein mAb)
Lu AF28996 (D₁/D₂ agonist)
Lu AG06466 (MGLLI)
Lu AF88434 (PDE1b inhibitor)
Lu AG09222 (PACAP mAb)
Lu AF87908 (Tau mAb)
"Treat and Prevent", migraine
Agitation in Alzheimer's disease
PTSD
Borderline Personality Disorder
Parkinson's disease
Schizophrenia
Tourette Syndrome
Schizophrenia
Parkinson's disease
Parkinson's disease
Neuropatic pain
Alzheimer's, schizophrenia (CIAS)
≥2023
≥2025
-2025
≥2025
≥2025
-2021
>2025
>2025
>2025
>2025
>2025
>2025
Migraine
Alzheimer's
13
CGRP: Calcitonin gene-related peptide. mGluR4 PAM: Positive Allosteric Modulator of metabotropic glutamate receptor 4. PDE: Phosphodiesterases. MGLLI:
Monoacylglycerol lipase inhibitor ("MAGlipase). PACAP: Pituitary adenylate cyclase-activating peptide.
LundbeckView entire presentation